In conclusion, neoadjuvant therapy with camrelizumab, trastuzumab, and chemotherapy demonstrates promising antitumor response and acceptable safety profile in HER2-positive resectable G/GEJ adenocarcinoma. This evidence concerns the gene ERBB2 and adenocarcinoma.